Neptune Wellness Solutions Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neptune Wellness Solutions in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Neptune Wellness Solutions stock.
View analyst ratings for Neptune Wellness Solutions or view top-rated stocks.

Wall Street analysts have given Neptune Wellness Solutions a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Neptune Wellness Solutions wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Neptune Wellness Solutions saw a decline in short interest in August. As of August 31st, there was short interest totaling 4,810,000 shares, a decline of 21.3% from the August 15th total of 6,110,000 shares. Based on an average daily volume of 1,650,000 shares, the days-to-cover ratio is presently 2.9 days. Currently, 3.0% of the shares of the stock are short sold.
View Neptune Wellness Solutions' Short Interest.

Neptune Wellness Solutions is scheduled to release its next quarterly earnings announcement on Monday, November 15th 2021.
View our earnings forecast for Neptune Wellness Solutions.

Neptune Wellness Solutions Inc (NASDAQ:NEPT) issued its quarterly earnings data on Wednesday, August, 11th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.11). The biotechnology company earned $10.08 million during the quarter, compared to analyst estimates of $8.87 million. Neptune Wellness Solutions had a negative trailing twelve-month return on equity of 74.86% and a negative net margin of 344.98%.
View Neptune Wellness Solutions' earnings history.

Neptune Wellness Solutions' stock was trading at $1.21 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NEPT shares have decreased by 52.8% and is now trading at $0.5710.
View which stocks have been most impacted by COVID-19.

Neptune Wellness Solutions issued an update on its first quarter 2022 earnings guidance on Thursday, July, 29th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $7.90 million-$9.48 million.

2 brokerages have issued 1-year price targets for Neptune Wellness Solutions' shares. Their forecasts range from $1.00 to $1.50. On average, they expect Neptune Wellness Solutions' stock price to reach $1.25 in the next twelve months. This suggests a possible upside of 118.9% from the stock's current price.
View analysts' price targets for Neptune Wellness Solutions or view top-rated stocks among Wall Street analysts.

Some companies that are related to Neptune Wellness Solutions include BioDelivery Sciences International (BDSI), Clearside Biomedical (CLSD), Antibe Therapeutics (ATBPD), Aerovate Therapeutics (AVTE), ANI Pharmaceuticals (ANIP), Locust Walk Acquisition (LWAC), Aeglea BioTherapeutics (AGLE), Vera Therapeutics (VERA), Pieris Pharmaceuticals (PIRS), Humanigen (HGEN), Athenex (ATNX), Tango Therapeutics (TNGX), Applied Therapeutics (APLT), Esperion Therapeutics (ESPR) and Cogent Biosciences (COGT).
View all of NEPT's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Neptune Wellness Solutions investors own include (CGC), Tilray (TLRY), Aurora Cannabis (ACB), Cronos Group (CRON), (APHA), Cara Therapeutics (CARA), Innovative Industrial Properties (IIPR), Zynerba Pharmaceuticals (ZYNE), Amarin (AMRN) and NewAge (NBEV).

Neptune Wellness Solutions trades on the NASDAQ under the ticker symbol "NEPT."

Neptune Wellness Solutions' stock is owned by a variety of retail and institutional investors. Top institutional investors include Murchinson Ltd. (1.19%), Penserra Capital Management LLC (0.94%), Susquehanna International Group LLP (0.00%), Cambria Investment Management L.P. (0.28%), Commonwealth Equity Services LLC (0.26%) and Group One Trading L.P. (0.00%).

NEPT stock was sold by a variety of institutional investors in the last quarter, including White Pine Capital LLC, Susquehanna International Group LLP, Bluefin Capital Management LLC, Bluefin Capital Management LLC, Alpine Global Management LLC, Bank of Montreal Can, Wolverine Trading LLC, and Cutler Group LP.

NEPT stock was bought by a variety of institutional investors in the last quarter, including Murchinson Ltd., Cambria Investment Management L.P., Penserra Capital Management LLC, Emerald Advisors LLC, Commonwealth Equity Services LLC, Goldman Sachs Group Inc., Morgan Stanley, and Simplex Trading LLC.

Shares of NEPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NEPT stock can currently be purchased for approximately $0.57.

Neptune Wellness Solutions has a market capitalization of $95.82 million and generates $35.45 million in revenue each year. The biotechnology company earns $-126,680,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis.

Neptune Wellness Solutions employs 58 workers across the globe.

The official website for Neptune Wellness Solutions is www.neptunecorp.com.

Neptune Wellness Solutions is headquartered at 545 PROMENADE DU CENTROPOLIS SUITE 100, LAVAL A8, H7T 0A3.

Neptune Wellness Solutions' mailing address is 545 PROMENADE DU CENTROPOLIS SUITE 100, LAVAL A8, H7T 0A3. The biotechnology company can be reached via phone at 45-0687-2262 or via email at [email protected].